INTRODUCTION
============

Hypercalcemia due to malignancy is relatively common and occurs in approximately 20-30 percent patients with cancer.[@r1] The pathogenesis of hypercalcemia due to malignancy is classified into three categories: humoral hypercalcemia of malignancy (HHM) due to parathyroid hormone related protein (PTHrP) secreted by tumor, local osteolytic hypercalcemia (LOH) caused by bone invasion, and 1,25-dihydroxyvitamin D~^3^~ (1,25(OH)~^2^~D~^3^~)-mediated hypercalcemia.[@r2]^,^[@r3] Among these categories, HHM is the most common, accounting for about 80% of all cases with hypercalcemia.[@r4]

Although multiple myeloma and adult T-cell leukemia/lymphoma are common hematological malignancies that cause hypercalcemia, malignant lymphoma can also be a cause of hypercalcemia.[@r5] In a previous report, approximately 5% patients with Hodgkin lymphomas (HL) and 13% patients with non-Hodgkin lymphomas (NHL) showed hypercalcemia.[@r6] 1,25(OH)~^2^~D~^3^~-mediated hypercalcemia was reported to be the most frequent in HL cases; almost all cases of hypercalcemia due to HL showed high serum 1,25(OH)~^2^~D~^3^~ level.[@r6] On the other hand, HHM has been frequently observed in NHL cases[@r7]; one study observed high serum 1,25(OH)~^2^~D~^3^~ levels only in one third of NHL cases with hypercalcemia.[@r6] In addition, the association between specific histological type of NHL and 1,25(OH)~^2^~D~^3^~ has not been confirmed, and cases of anaplastic large cell lymphoma (ALCL) with 1,25(OH)~^2^~D~^3^~-mediated hypercalcemia has not been reported.

We herein report a case of hypercalcemia due to ALCL, ALK-negative, which seems to be producing 1,25(OH)~^2^~D~^3^~.

CASE REPORT
===========

The patient was an 80-year-old Japanese man with a past medical history of hypertension, dyslipidemia, and acute myocardial infarction (percutaneous coronary intervention was performed 4 years ago). He presented with right cervical lymphadenopathy and cervical pain 1 month before admission and visited a local clinic. He was administered cefcapene pivoxil and prednisolone; however, the symptoms did not improve. Three days before admission, he was referred to our hospital; his blood test showed the following results: corrected serum calcium level, 13.0 mg/dL; C-reactive protein (CRP) level, 6.87 mg/dL; and lactate dehydrogenase (LDH) level, 1453 IU/L. Serum calcium level increased rapidly to 14.0 mg/dL in 3 days and he was hospitalized urgently.

On admission, his consciousness was lucid, body temperature was 36.9°C, blood pressure was 116/77 mmHg, pulse rate was 66/min, and oxygen saturation was 94% on room air. Eye examination showed no anemia or jaundice. Head and neck examination revealed right mandibular and cervical lymphadenopathies, sized 10-20 mm, with tenderness. No other palpable superficial lymph nodes were found. Breath and heart sounds were normal. Abdominal examination showed no hepatosplenomegaly. Pitting edema was confirmed in the lower extremities. His general condition was poor, and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was 4. B symptoms (fever, night sweats, and weight loss) were not observed.

We investigated the cause of hypercalcemia after admission. In the laboratory data ([Table 1](#t1){ref-type="table"}), blood examination revealed that 1,25(OH)~^2^~D~^3^~ level was high, 25-hydroxyvitamin D~^3^~ level was normal, intact parathyroid hormone level was low, PTHrP was not detected, calcitonin level was normal, and angiotensin-converting enzyme level was low. Serum monoclonal protein and urine Bence-Jones protein were not detected. Human T-cell Leukemia Virus type 1 antibody and QuantiFERON^®^ tests were negative. Computed tomography (CT) showed lymphadenopathies in the right neck, right supraclavicular, superior mediastinal, and right axillary nodes, and under the tracheal branch and pancreas head. Evident neoplastic bone lesions were not found ([Figure 1](#f1){ref-type="fig"}).

###### Laboratory data on admission

  ------ ------------ ------ -- ---------- ------- ------- -- --------------------- ---------------- --------
  RBC    476×104      /μL       γ-GTP      45      IU/L       IgG                   1036             mg/dL
  Hb     14.4         g/dL      ALP        275     IU/L       IgA                   155              mg/dL
  Hct    43.3         \%        ChE        189     mg/dL      IgM                   142              mg/dL
  WBC    5680         /μL       T-Bil      0.6     mg/dL      aPTT                  33.0             sec
  Neut   80.8         \%        BUN        26      mg/dL      PT-INR                1.04             
  Lym    8.8          \%        Cre        1.1     mg/dL      HTLV-1 antibody       (-)              
  Eos    1.6          \%        Na         138     mEq/L      QuantiFERON test      (-)              
  Bas    0.7          \%        K          4.6     mEq/L      Serum M-protein       (-)              
  Mon    8.1          \%        Cl         99      mEq/L      Urine BJP             (-)              
  Plt    21.6×10^4^   /μL       Ca         14      mg/dL      1,25(OH)~^2^~D~^3^~   227 (20-60)      pg/mL
  TP     7.1          g/dL      I-P        4.6     mg/dL      25(OH)D~^3^~          16.1 (≤20)       ng/mL
  Alb    3.2          g/dL      CRP        10.16   mg/dL      intact PTH            \<3.00 (15-65)   pg/mL
  AST    217          IU/L      sIL-2R     8685    IU/mL      PTHrP                 \<1.00 (\<1.1)   pmol/L
  ALT    40           IU/L      Ferritin   690     ng/mL      Calcitonin            2.0 (≤5.15)      pg/mL
  LDH    1549         IU/L      β2MG       2.0     mg/L       ACE                   2.3 (6.6-21.4)   IU/L
  ------ ------------ ------ -- ---------- ------- ------- -- --------------------- ---------------- --------

RBC: red blood cell, Hb: hemoglobin, Hct: hematocrit, WBC: white blood cell, Neut: neutrophil, Lym: lymphocyte, Eos: eosinophil, Bas: basophil, Mon: monocyte, Plt: platelet, TP: total protein, Alb: albumin, AST: aspartate transaminase, ALT: alanine transaminase, LDH: lactate dehydrogenase, γ-GTP: γ-glutamyl transpeptidase, ALP: alkaline phosphatase, ChE: cholinesterase, T-Bil: total bilirubin, BUN: blood urea nitrogen, Cre: creatinine, I-P: inorganic phosphate, CRP: C-reactive protein, sIL-2R: soluble interleukin-2 receptor, β2MG: β2-microglobulin, APTT: activated partial thromboplastin time, PT-INR: prothrombin time-international normalized ratio, HTLV-1: human T-lymphotropic virus type 1, M-protein: monoclonal protein, BJP: Bence-Jones protein, 1,25(OH)~^2^~D~^3^~: 1,25-dihydroxyvitamin D~^3^~, 25(OH)D~^3^~: 25-hydroxyvitamin D~^3^~, PTH: parathyroid hormone, PTHrP: parathyroid hormone related protein, ACE: angiotensin-converting enzyme

![Systemic computed tomography (CT) scan images on admission.\
Systemic CT scan showed lymphadenopathies at (*A*) right neck, right supraclavicular, superior mediastinal, and right axillary lymph nodes; (*B*) under tracheal branch; and (*C*) under tracheal branch. Evident neoplastic bone lesions were not found.](jslrt-59-22-g001){#f1}

On the 1st hospital day, we started massive saline infusion, furosemide, and calcitonin derivative to improve hypercalcemia. Cervical lymph node biopsy was performed on the 5th hospital day. Hematoxylin-eosin staining showed large abnormal lymphocytes in the lymph node. Immunohistochemistry revealed that tumor cells were CD3 negative, CD20 negative, CD4 positive, CD8 negative, CD30 positive, ALK negative, TIA-1 positive, PAX5 negative, CD68 negative, AE1/AE3 negative, and Granzyme B negative. In addition, CD68-positive cells, which were considered to be macrophage- or monocyte-like cells, were observed in the microenvironment of tumor cells ([Figure 2](#f2){ref-type="fig"}). Chromosomal abnormalities could not be detected from G-banding because enough metaphase cells were not obtained. Bone marrow biopsy showed no tumor invasion. Based on the above findings, he was diagnosed with ALCL, ALK-negative (Clinical stage: IIIA, International Prognostic Index (IPI): high-risk).

![Pathological images of cervical lymph node biopsy on the 5th hospital day.\
Hematoxylin-eosin (HE) staining showed large atypical lymphocytes growing in the tissue. Immunostaining revealed that tumor cells were CD3(-), CD20(-), CD4(+), CD8(-), CD30(+), ALK(-), TIA-1(+), PAX5(-), CD68(-), AE1/AE3(-) and Granzyme B(-). CD68-positive histiocytes were observed around the tumor cells.](jslrt-59-22-g002){#f2}

Although the most common chemotherapy regimen for ALCL, ALK-negative is CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone), we selected THP-COP (therarubicin, cyclophosphamide, vincristine, and prednisolone) because the patient had a past medical history of acute myocardial infarction. On the 8th hospital day, ECOG-PS was noted to be very poor; therefore, we started 50% dose of THP-COP. At the end of the 1st cycle of THP-COP, CT showed 70% tumor reduction and we confirmed partial response (PR). His general condition was improving, and his corrected serum calcium and 1,25(OH)~^2^~D~^3^~ returned to the normal range, along with decreases in LDH and soluble interleukin-2 receptor (sIL2-R) levels ([Figure 3](#f3){ref-type="fig"}). On the 28th hospital day, we started the 2nd cycle with a 75% dose of THP-COP. Complete response (CR) with 90% tumor reduction was confirmed by CT at the end of the cycle. On the 48th hospital day, we started the 3rd cycle with 75% dose of THP-COP. On the 51st hospital day, he was discharged because he was able to receive outpatient chemotherapy. His corrected serum calcium level was 9.7 mg/dL and 1,25(OH)~^2^~D~^3^~ level was 31.8 ng/dL. Until the 6th and final cycle of THP-COP, CR was maintained, and corrected serum calcium and 1,25(OH)~^2^~D~^3^~ levels did not increase again. We confirmed complete metabolic response by ^18^F-fluorodeoxy glucose positron emission tomography at the end of the 6th cycle ([Figure 4](#f4){ref-type="fig"}). At the latest follow-up 10 months, he has maintained CR.

![Transition of lactate dehydrogenase (LDH), soluble interleukin-2 receptor (sIL2-R), corrected serum calcium (corrected Ca), and 1,25-dihydroxyvitamin D~^3^~ (1,25(OH)~^2^~D~^3^~).\
Corrected Ca and 1,25(OH)~^2^~D~^3^~ are improved in parallel with LDH and sIL2-R. Day 1 is the date of hospitalization. THP: therarubicin, CPA: cyclophosphamide, VCR: vincristine, PSL: prednisolone, PA: partial response, CR: complete response.](jslrt-59-22-g003){#f3}

![^18^F-fluorodeoxy glucose positron emission tomography (FDG-PET) images after 6th cycle of THP-COP therapy.\
FDG-PET showed that lymphadenopathy at (*A*) right neck, right supraclavicular, superior mediastinal, and right axillary lymph nodes; (*B*) subcarinal lymph nodes; and (*C*) pancreas head had disappeared. No significant accumulations of FDG were observed (*D*). We confirmed complete metabolic response.](jslrt-59-22-g004){#f4}

DISCUSSION
==========

This case showed 1,25(OH)~^2^~D~^3^~-mediated hypercalcemia because serum 1,25(OH)~^2^~D~^3^~ level was high, and multiple myeloma, hyperparathyroidism, medullary thyroid cancer, LOH, or granulomatous disease such as sarcoidosis or tuberculosis were not considered. Response to the treatment for ALCL, ALK-negative (tumor reduction and decreases of LDH and sIL2-R) was correlated to normalizations of corrected serum calcium and 1,25(OH)~^2^~D~^3^~ levels, and they had not increase again in the remission phase ([Figure 3](#f3){ref-type="fig"}). Moreover, as in the previous reports of malignant lymphomas with 1,25(OH)~^2^~D~^3^~-mediated hypercalcemia,[@r8]^-^[@r18] responses to treatment for malignant lymphomas were correlated to normalizations of corrected serum calcium and 1,25(OH)~^2^~D~^3^~ levels ([Table 2](#t2){ref-type="table"}).[@r8]^,^[@r11]^,^[@r12]^,^[@r15]^-^[@r17] From the above reports, we suspected that ALCL cells were associated with 1,25(OH)~^2^~D~^3^~ production in this case.

###### Previous reports of malignant lymphoma with 1,25(OH)~2~D~3~-mediated hypercalcemia

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  year   Previous reports                       Onset age   Sex   Classification of the lymphoma   Primary site     Treatment             1,25(OH)2D3 (pg/mL)   Serum calcium (mg/dL)   Treatment response or outcome               
  ------ -------------------------------------- ----------- ----- -------------------------------- ---------------- --------------------- --------------------- ----------------------- ------------------------------- ----------- ---------------------
  2018   Nakayama S, *et al*.[@r8]              78          M     DLBCL (non-GCB)                  Nasal cavity     R-CHOP                81.7                  59.2                    10.4                            8.8         CR

  2018   Chams S, *et al*.[@r9]                 83          M     AITL                             NA               Untreated             85.4                  NA                      11.7                            NA          Death (PD)

  2016   Abaroa-Salvatierra A, *et al*.[@r10]   81          M     DLBCL                            Adrenal          R-CVP                 90                    NA                      14                              NA          Death (PD)

  2016   Mir SA, *et al*.[@r11]                 65          M     DLBCL                            Adrenal          R-CHOP                213.4                 NA                      14.2                            8.9         CR

  2006   Gupta R, *et al*.[@r12]                79          F     Hodgkin lymphoma                 Axillary LN      Chemotherapy          248                   Normal                  21.0                            10.7        CR

  2003   Hewison M, *et al*.[@r13]              75          M     Large intermediate grade BCL     Spleen           Splenectomy           140                   20\*                    12.7                            Normal      NA

  1999   Adams JS, *et al*.[@r14]               29          M     BCL (small non-cleaved)          NA               Hydroxychloroquine†   96\*                  70\*                    11.9\*                          11.5\*      NA

                                                77          F     BCL (small non-cleaved)          NA               Hydroxychloroquine†   94\*                  70\*                    11.3\*                          10.8\*      NA

                                                74          F     BCL (small non-cleaved)          NA               CHOP                  125\*                 40\*                    14.3\*                          9.4\*       NA

                                                67          F     BCL (small non-cleaved)          NA               CHOP                  86\*                  14\*                    13.1\*                          10.0\*      NA

  1998   Moore JJ, *et al*.[@r15]               48          M     DLBCL\                           Para-vertebral   CHOP, BMT             206                   Decreased               15.2                            Decreased   Death (BMT related)
                                                                  (T-cell rich)                                                                                                                                                     

  1991   Scheinman SJ, *et al*.[@r16]           58          M     angiocentric lymphoma            NA               CHOP                  170                   Normal                  15.1                            Normal      CR

  1988   Mercier RJ, *et al*.[@r17]             40          M     Hodgkin lymphoma                 NA               BCVPP                 248                   21.6                    14                              Normal      CR

  1986   Schaefer K, *et al*.[@r18]             74          F     Hodgkin lymphoma                 NA               Prednisolone          105\*                 40\*                    14.2                            8.5\*       NA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DLBCL: diffuse large B-cell lymphoma; GCB: germinal center B-cell-like; AITL: angioimmunoblastic T-cell lymphoma; BCL: B-cell lymphoma; NA: not available; LN: lymph node; R: rituximab; CHOP: cyclophosphamide(CPA), doxorubicin, vincristine(VCR), prednisolone(PSL); CVP: CPA, VCR, PSL; BMT: bone marrow transplantation; BCVPP: carmustine, CPA, vinblastine, procarbazine, PSL; Tx: treatment; †: hydroxychloroquine is reported to reduce serum calcium level in sarcoidosis; \*: read from figure (value is not stated); CR: complete response; CYP27B1: 25-hydroxyvitamin D3-1α-hydroxylase.

25-hydroxyvitamin D~^3^~-1α-hydroxylase (CYP27B1) have been reported to be associated with 1,25(OH)~^2^~D~^3^~ production.[@r19]^,^[@r20] CYP27B1 acts primarily on the renal proximal tubes; however, it is also expressed in many extra-renal tissues including macrophages.[@r19] Expression of CYP27B1 has been also reported in various malignant tumors such as colon cancer, breast cancer, and prostate cancer.[@r19] In these cancers with hypercalcemia, the regulation of CYP27B1 by 1,25(OH)~^2^~D~^3^~ within a negative feedback loop is believed to be lost in malignant cells because of the gene mutation.[@r19] On the other hand, in granulomatous diseases such as sarcoidosis and tuberculosis, hypercalcemia is induced by the hyperactivity of CYP27B1 in the macrophages in granuloma. This is associated with cytokines such as interferon-γ, tumor necrosis factor-α and interleukin-1,2,15.[@r20]^-^[@r22] In this case, inflammatory reaction involving the elevation of CRP level was observed. Therefore, it can be concluded that macrophages and cytokines might be associated with hypercalcemia.

In previous reports of malignant lymphomas with 1,25(OH)~^2^~D~^3^~ production ([Table 2](#t2){ref-type="table"}), two cases expressed CYP27B1. One was expressed in lymphoma cells[@r8] and the other in the macrophages around lymphoma cells.[@r13] As mentioned above, there are two theories as to the pathogenesis of 1,25(OH)~^2^~D~^3^~ production in lymphoma: CYP27B1 mutation in tumor cells, and CYP27B1 hyperactivity in macrophages around tumor cells; these cases suggest that both theories are possible. The letter theory is possibly associated with cytokines produced by the lymphoma. It is currently unknown whether it is the tumor cells or the tumor microenvironment that produce 1,25(OH)~^2^~D~^3^~. In our case, ALCL cells or tumor microenvironment were assumed to produce 1,25(OH)~^2^~D~^3^~ because histiocytes and macrophages were confirmed in the tumor microenvironmental cells ([Figure 2](#f2){ref-type="fig"}). However, we could not identify 1,25(OH)~^2^~D~^3^~ production in either lymphoma or tumor microenvironmental cells.

Though we could not provide any evidence of a direct relationship between lymphoma and 1,25(OH)~^2^~D~^3^~ production, we assumed that the lymphoma was associated with 1,25(OH)~^2^~D~^3^~ production in some way because treatment response showed correlation with normalization of 1,25(OH)~^2^~D~^3^~ levels. The tumor itself, like other malignancies or macrophage-like granulomatous diseases seems to produce 1,25(OH)~^2^~D~^3^~ because both have been reported previously in malignant lymphoma.[@r8]^,^[@r13]

In conclusion, although 1,25-dihydroxyvitamin D~^3^~-producing cells in ALCL, ALK-negative could not be directly identified, we demonstrated a case of hypercalcemia due to the production 1,25(OH)~^2^~D~^3^~ by ALCL, ALK-negative. To our knowledge, this is the first report of ALCL with 1,25(OH)~^2^~D~^3^~-mediated hypercalcemia. Further studies and more cases will be needed to investigate the exact pathogenesis of 1,25(OH)~^2^~D~^3^~ production.
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